Targeted Strategies for Today's Evolving Markets

MissionIR Blog

Category Archives: International Stem Cell Corp. ISCO

International Stem Cell Corp. (ISCO) Announces Successful Intracranial Cell Transplantation in Phase I Clinical Study of ISC-hpNSC

Before the opening bell, International Stem Cell Corp. (OTCQB: ISCO) announced that the first patient in its ongoing phase I clinical trial of human parthenogenetic neural stem cells (ISC-hpNSC) for the treatment of moderate to severe Parkinson’s disease has undergone … Continue reading

Posted in International Stem Cell Corp. ISCO | Leave a comment

International Stem Cell Corp. (ISCO) Reduces Risk through Its Commercial Operations

Although cash burn for International Stem Cell Corp. (OTCQB: ISCO) currently stands at over $0.5 million per month, a number likely to increase with the progression of its clinical trials for Parkinson’s disease (PD), risks have been mitigated thanks to … Continue reading

Posted in International Stem Cell Corp. ISCO | Leave a comment

International Stem Cell Corporation (ISCO) Insiders Inspire Confidence with Share Purchases

Recent Form 4 filings with the U.S. Securities and Exchange Commission indicate that the management team of International Stem Cell Corporation (OTCQB: ISCO) is bullish on the company. Form 4 is a Statement of Changes of Beneficial Ownership of Securities … Continue reading

Posted in International Stem Cell Corp. ISCO | Leave a comment

International Stem Cell Corp. (ISCO) Using Extract from Stem Cells to Produce Cosmetic Skin Care Line

Stem cells have near-limitless abilities. They divide, reproduce, and build on each other to repair and regenerate tissue. Stem cells are most interesting for their ability to renew themselves and to differentiate into specific cells. Every single time a stem … Continue reading

Posted in International Stem Cell Corp. ISCO | Leave a comment

International Stem Cell Corp. (ISCO) Looking to Transform Parkinson’s Disease Treatment with ISC-hpNSC™ Clinical Trial

Last month, International Stem Cell Corp. (OTCQB: ISCO) published the results of its 12-month pre-clinical, non-human primate study demonstrating the safety and efficacy of its proprietary human parthenogenetic stem cell-derived neural stem cells (ISC-hpNSC™). These findings highlighted the efficacy of … Continue reading

Posted in International Stem Cell Corp. ISCO | Leave a comment

International Stem Cell Corp. (ISCO) Avoiding Ethical Issues with Stem Cells Derived From Unfertilized Eggs

Human pluripotent stem cells are a type of cell that is self-replicating. In simple terms, they clone themselves. These are typically derived from human embryos and have the possibility to grow into virtually any type of cell in the body. … Continue reading

Posted in International Stem Cell Corp. ISCO | Leave a comment

International Stem Cell Corp. (ISCO) Neural Stem Cell Therapy – Ethical, Effective, and Homegrown

A news story out this week (http://dtn.fm/SW1v5) in the MIT Technology Review recounts the lamentable tale of a man (Jim Gass) who used to be chief legal counsel for storied electrical manufacturer Sylvania – for whom a desperate search to … Continue reading

Posted in International Stem Cell Corp. ISCO | Leave a comment

International Stem Cell Corp. (ISCO) Protecting its Technology Worldwide

A patent is essentially a government license that gives certain rights to the patent holder, excluding others from making, using, or selling a particular product or invention without permission. According to WIPO’s 2015 World Intellectual Property Indicators Report, there have … Continue reading

Posted in International Stem Cell Corp. ISCO | Leave a comment

Buy One get One Free with International Stem Cell Corporation (ISCO)

The recent initiation report on International Stem Cell Corporation (OTCQB: ISCO) by Edison Investment Research looks at the company from a novel perspective. Although described as ‘an early-stage cell therapy company currently in Phase I/IIa clinical trials to treat Parkinson’s … Continue reading

Posted in International Stem Cell Corp. ISCO | Leave a comment

International Stem Cell Corp. (ISCO) Advancing Clinical Development Program for Parkinson’s Disease

International Stem Cell Corp. (OTCQB: ISCO) is a biotechnology company that works with parthenogenesis to treat diseases of the eyes, the nervous system, the liver, and more. Currently, ISCO is preparing for a phase I clinical trial of its proprietary … Continue reading

Posted in International Stem Cell Corp. ISCO | Leave a comment